JLC's Binex merger plan hit snag

Published: 2008-04-17 06:56:00

Updated: 2008-04-17 06:56:00

JLC says that it has failed to acquire Binex due to opposition of its large shareholders, although both companies signed a take-over contract with Binex, a biopharmaceutical firm on January 12.

JLC is keen on Binex's management and shares instead of investment on research and development proje...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK